Parabolic Drugs Limited get approval from Ranbaxy for supply of regulated 6 APA for Ranbaxy’s US markets from PDL’s Panchkula facility, subsequent to PDL filing DMF for USFDA approval in 2005.

Ranbaxy has been informed by USFDA that they can now start sourcing 6 APA from Parabolic’s Panchkula facility for Ranbaxy’s US markets. This approval came subsequent to PDL filing a DMF for USFDA approval in 2005 for its Panchkula 6 APA facility. This places PDL in a strategic position in the Pencillins business and also demonstrates PDL’s ability to put up World Class manufacturing facilities.

See also  Minivet, a Mauritius based FII picks up 4.93% stake in PDL

Category: Uncategorized